WallStreetZenWallStreetZen

NASDAQ: CDXC
Chromadex Corp Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for CDXC

Based on 2 analysts offering 12 month price targets for Chromadex Corp.
Min Forecast
$6.00+75.95%
Avg Forecast
$6.00+75.95%
Max Forecast
$6.00+75.95%

Should I buy or sell CDXC stock?

Based on 2 analysts offering ratings for Chromadex Corp.
Strong Buy
Strong Buy
1 analysts 50%
Buy
1 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their CDXC stock forecasts and price targets.

CDXC stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-08-09
lockedlocked$00.00+00.00%2024-06-12

1 of 1

Forecast return on equity

Is CDXC forecast to generate an efficient return?
Company
40.79%
Industry
-273.42%
Market
52.42%
CDXC's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is CDXC forecast to generate an efficient return on assets?
Company
23.19%
Industry
21.67%
CDXC is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

CDXC earnings per share forecast

What is CDXC's earnings per share in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
$0.01
Avg 2 year Forecast
$0.09
Avg 3 year Forecast
$0.17

CDXC revenue forecast

What is CDXC's revenue in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
$94.7M+10.65%
Avg 2 year Forecast
$114.9M+34.2%
Avg 3 year Forecast
$136.9M+59.96%
CDXC's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

CDXC revenue growth forecast

How is CDXC forecast to perform vs Biotechnology companies and vs the US market?
Company
16.12%
Industry
55.36%
Market
8.81%
CDXC's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
CDXC's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

CDXC vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CDXC$3.41$6.00+75.95%Strong Buy
TSVT$5.00$7.33+46.66%Buy
LXEO$7.96$24.00+201.51%Strong Buy
RZLT$4.78$11.57+142.07%Strong Buy
MRSN$2.06$4.00+94.17%Buy
View Top Biotech Stocks

Chromadex Stock Forecast FAQ

Is Chromadex Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: CDXC) stock is to Strong Buy CDXC stock.

Out of 2 analysts, 1 (50%) are recommending CDXC as a Strong Buy, 1 (50%) are recommending CDXC as a Buy, 0 (0%) are recommending CDXC as a Hold, 0 (0%) are recommending CDXC as a Sell, and 0 (0%) are recommending CDXC as a Strong Sell.

If you're new to stock investing, here's how to buy Chromadex stock.

What is CDXC's earnings growth forecast for 2024-2026?

(NASDAQ: CDXC) Chromadex's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.79%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 20.11%.

Chromadex's earnings in 2024 is -$1,352,000.On average, 3 Wall Street analysts forecast CDXC's earnings for 2024 to be $759,331, with the lowest CDXC earnings forecast at -$759,331, and the highest CDXC earnings forecast at $2,277,994. On average, 3 Wall Street analysts forecast CDXC's earnings for 2025 to be $6,583,403, with the lowest CDXC earnings forecast at $2,277,994, and the highest CDXC earnings forecast at $9,111,976.

In 2026, CDXC is forecast to generate $12,528,968 in earnings, with the lowest earnings forecast at $8,352,645 and the highest earnings forecast at $16,705,290.

What is CDXC's revenue growth forecast for 2024-2026?

(NASDAQ: CDXC) Chromadex's forecast annual revenue growth rate of 16.12% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 55.36%, and while it is forecast to beat the US market's average forecast revenue growth rate of 8.81%.

Chromadex's revenue in 2024 is $85,583,000.On average, 2 Wall Street analysts forecast CDXC's revenue for 2024 to be $7,190,868,074, with the lowest CDXC revenue forecast at $7,099,748,310, and the highest CDXC revenue forecast at $7,281,987,838. On average, 2 Wall Street analysts forecast CDXC's revenue for 2025 to be $8,720,920,784, with the lowest CDXC revenue forecast at $8,656,377,618, and the highest CDXC revenue forecast at $8,785,463,951.

In 2026, CDXC is forecast to generate $10,395,246,455 in revenue, with the lowest revenue forecast at $10,395,246,455 and the highest revenue forecast at $10,395,246,455.

What is CDXC's forecast return on assets (ROA) for 2024-2026?

(NASDAQ: CDXC) forecast ROA is 23.19%, which is higher than the forecast US Biotechnology industry average of 21.67%.

What is CDXC's Price Target?

According to 2 Wall Street analysts that have issued a 1 year CDXC price target, the average CDXC price target is $6.00, with the highest CDXC stock price forecast at $6.00 and the lowest CDXC stock price forecast at $6.00.

On average, Wall Street analysts predict that Chromadex's share price could reach $6.00 by Aug 9, 2025. The average Chromadex stock price prediction forecasts a potential upside of 75.95% from the current CDXC share price of $3.41.

What is CDXC's Earnings Per Share (EPS) forecast for 2024-2026?

(NASDAQ: CDXC) Chromadex's current Earnings Per Share (EPS) is -$0.02. On average, analysts forecast that CDXC's EPS will be $0.01 for 2024, with the lowest EPS forecast at -$0.01, and the highest EPS forecast at $0.03. On average, analysts forecast that CDXC's EPS will be $0.09 for 2025, with the lowest EPS forecast at $0.03, and the highest EPS forecast at $0.12. In 2026, CDXC's EPS is forecast to hit $0.17 (min: $0.11, max: $0.22).

What is CDXC's forecast return on equity (ROE) for 2024-2026?

(NASDAQ: CDXC) forecast ROE is 40.79%, which is considered strong.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.